Lv6
1630 积分 2023-06-12 加入
POS0656 TOLERABILITY AND EFFICACY OF BMS-986353 (CC-97540), A CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY MANUFACTURED USING A NEXT-GENERATION PROCESS FOR SYSTEMIC SCLEROSIS: UPDATED DATA FROM THE PHASE 1 BREAKFREE-1 STUDY
14小时前
求助中
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
1天前
已完结
Systemic sclerosis: one year in review 2025
1天前
已完结
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual
7天前
已完结
EULAR 2025: European Congress of Rheumatology
8天前
已关闭
POS0656 TOLERABILITY AND EFFICACY OF BMS-986353 (CC-97540), A CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY MANUFACTURED USING A NEXT-GENERATION PROCESS FOR SYSTEMIC SCLEROSIS: UPDATED DATA FROM THE PHASE 1 BREAKFREE-1 STUDY
8天前
已关闭
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index
8天前
已完结
POS0656 TOLERABILITY AND EFFICACY OF BMS-986353 (CC-97540), A CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY MANUFACTURED USING A NEXT-GENERATION PROCESS FOR SYSTEMIC SCLEROSIS: UPDATED DATA FROM THE PHASE 1 BREAKFREE-1 STUDY
15天前
已关闭
Development and consequences of red blood cell autoantibodies: warm autoimmune hemolytic anemia
17天前
已关闭
Rituximab for myasthenia gravis
17天前
已完结
皖公网安备34019202002308
